Systemic calcium-binding and transport sites

The term Systemic calcium-binding and transport sites refers to the integrated physiological network of proteins and receptors responsible for maintaining calcium homeostasis across the body, primarily within the intestines, kidneys, and bones. This system is governed by key regulatory molecules such as the calcium-sensing receptor (CaSR), which monitors extracellular calcium levels (UniProt P41180), and the vitamin D receptor (VDR), which modulates the expression of calcium-handling proteins (UniProt P11473). Essential components of this network include epithelial calcium channels like TRPV5 and TRPV6 (UniProt Q9NQA5, Q9H1D0), intracellular shuttle proteins such as calbindin-D9k and calbindin-D28k (UniProt P05937, P05940), and basolateral exporters like the plasma membrane Ca2+-ATPase (PMCA). Pharmacologically, these sites are targeted to manage mineral metabolism disorders such as osteoporosis, hyperparathyroidism, and chronic kidney disease. Drugs like cinacalcet act as calcimimetics by increasing CaSR sensitivity, while vitamin D analogs enhance intestinal calcium absorption by upregulating transport proteins. Additionally, therapeutic minerals like strontium ranelate can compete for these binding sites to promote bone formation (ATSDR 2004).

Other names

Calcium homeostasis systemCalcium transport proteinsCalcium-binding proteinsCa2+ transport system

Activation of the calcium-sensing receptor (CaSR) to inhibit PTH secretion, activation of the vitamin D receptor (VDR) to increase expression of transport proteins, and direct competition for calcium-binding sites in bone and soft tissues.